Cancer clinical trials in the region Île-de-France
647 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT07353957
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
4 recruiting sites
Merus
Phase 2
Lung cancer
#NCT06855771
#2024-519814-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06682988
#2024-517184-23-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required folate alpha receptor score
Greater than or equal to 75%
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
8 recruiting sites
Abbvie
Phase 2
Thyroid and adrenal gland cancer
#NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
14 recruiting sites
Centre Léon Bérard
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06235398
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required medullary blasts
< 5 %
5-10 %
Excluded genetic anomalies
NPM1
Excluded previous treatments
Chemotherapy
2 recruiting sites
Phase 2
Thyroid and adrenal gland cancer
#NCT07016230
#2024-515847-47-00
Cohorte 2 Cancer médullaire de la thyroïde (CMT) de haut grade
Required histologic types
Thyroid cancer
Required histologic sub types
Medullary carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 2
Pancreas cancer
Liver and bile duct cancer
Stomach and esophageal cancer
Sarcoma and GIST
Small intestine and appendix cancer
#NCT06333314
#2023-505298-34-00
Required histologic types
Stomach
Oesogastric junction
Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma
Ampullary carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1)
CPS Positive (1 <= X < 5)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
7 recruiting sites
UNICANCER
Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06333314
#2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
7 recruiting sites
UNICANCER
Phase 2
Acute leukemia
#NCT07007052
#2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
1 recruiting site
French Innovative Leukemia Organisation (FILO)